Oral presentations
Date: Tuesday, 2 August 2022
Time: 15:30-16:30
Room: Bolivar – B
| Combination therapy for chagas disease – pyrrolopyrimidine series Marco M, Braillard S, Thomas J, Wall R, Carvalho S, MacLean L, Paterson C, Stojanovski L, Charman SA, Keenan M, Avery VM, Kelly J, DeRycker M, Wyllie S, Miles TJ, Chatelain E, Read K, Gonzalez S Presented by Maria Marco, GlaxoSmithKline, Spain |
Time: 18:00-19:00
Room: Bolivar – B
| A phase I single oral ascending dose study in healthy subjects of the benzoxaborole derivative DNDi-6148, a novel drug candidate for leishmaniasis Jean-Yves Gillon, Head of Translation Sciences, DNDi |
Date: Wednesday, 3 August 2022
Time: 15:30-16:30
Room: Bolivar – A
| In vitro and in vivo combination profiling for leishmaniasis treatment using a back-translational approach Kirsten Gillingwater, Programme Manager, DNDi |
Time: 18:00-19:00
Room: Guacamayo
| Efficacy and safety of a 14-day combination regimen of Paromomycin and Miltefosine for the treatment of patients with primary visceral leishmaniasis in Eastern Africa Alexandra Solomos, Senior Clinical Project Manager, DNDi |
| Efficacy and safety of short course combination regimens of liposomal amphotericin b and miltefosine for treatment of PKDL in the Indian subcontinent Sunder S, Pandey K, Mondal D, Raja S, Pratap Singh B, Singh A, Singh OP, Alvar J, Rijal S, Alves F |
| Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: a collaborative retrospective study del Mar Castro M, Rode J, Machado PRL, Llanos-Cuentas A, Hueb M, Fernandes Cota G, Rojas IVV, Orobio Y, Oviedo Sarmiento O, Rojas E, Quintero J, Fernandes Pimentel MI, Soto J, Suprien C, Alvarez F, Pilar Ramos A, Basílio dos Santos Arantes R, da Silva R, Arenas CM, Vélez ID, Rosandiski Lyra M, Gore Saravia N, Arana B, Alexander N Presented by Maria del Mar Castro, Centro Internacional de Entrenamiento e Investigaciones Médicas, Colombia |
Date: Friday, 5 August 2022
Time: 15:30-16:30
Room: Bolivar – A
| Safety and efficacy of two new treatments for patients with post-kala-azar dermal leishmaniasis: a randomized parallel arm open label study in Sudan Samuel Teshome Tesema, Senior Clinical Project Manager, DNDi |
Time: 18:00-19:00
Room: Bolivar – A
| Safety, pharmacokinetics and immune effects in healthy volunteers of CPG ODN D35, a TOLL-like receptor 9 agonist therapeutic for leishmaniasis Blesson S, Bonnet B, Blum B, Gillon J-Y, Verthelyi D, Caplain H, Goncalvez J, Yousfi R, Wu Tann L, Hutchings S, Koch A, Arana B Presented by Séverine Blesson, Senior Clinical Trial Manager, DNDi |
| First in human study in healthy subjects to assess the safety, tolerability and pharmacokinetics of DNDI-0690, a novel oral drug candidate for leishmaniasis Blesson S, Koch A, Sidhu S, Bonnet B, Bobrie G, Caplain H, Alves F, Gillon J-Y Presented by Séverine Blesson, Senior Clinical Trial Manager, DNDi |
| DNDI-6174: a preclinical candidate from a novel chemical class and mechanism of action to tackle leishmaniasis Stéphanie Braillard, NonClinical Development Senior Manager |
